Post-hoc analysis of two clinical trials examining Customized Adherence Enhancement plus long acting injectable antipsychotic (CAE-L) in high-risk individuals with serious mental illness

Long-acting injectable antipsychotic (LAI) medications are a practical option for promoting treatment adherence in high risk individuals with serious mental illness (SMI) (Alphs et al., 2015, 2014; West et al., 2008). Treatment of these individuals may be optimized when LAI is combined with a quality psychosocial intervention to modify a patient's long-term attitudes and behaviors (Velligan et al., 2008). Customized Adherence Enhancement (CAE) is a manualized behavioral intervention targeting adherence specific barriers to improve medication adherence by Sajatovic et al.

Source: Schizophrenia Research - July 19, 2018 Category: Psychiatry Authors: Christine M. Collins, Michelle E. Aebi, Jennifer B. Levin, Curtis Tatsuoka, Kristin A. Cassidy, Martha Sajatovic Tags: Letter to the Editor Source Type: research